ESMO 2024 Industry Satellite Symposium

Setting a new benchmark for ALK+ aNSCLC targeted therapy

Sunday 15 September 2024 18:30–20:00 CEST

Santander Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain



Agenda





Professor Tony Mok The Chinese University of Hong Kong, Hong Kong SAR, China

Welcome and introduction

Professor Tony Mok

Latest data in the 1L ALK+ aNSCLC treatment landscape

Dr Justin Gainor

Optimising 1L treatment in clinical practice

Professor Tony Mok

Practical strategies for managing adverse events

Professor Enriqueta Felip



Professor Enriqueta Felip

Vall d'Hebron University Hospital, Barcelona, Spain

Dr Justin Gainor

Boston, USA

Massachusetts General Hospital,

ALK+ aNSCLC treatment expectations now and in the future

Professor Tony Mok



1L, first-line; ALK, anaplastic lymphoma kinase; aNSCLC, advanced non-small cell lung cancer.

This Industry-Sponsored Symposium is organised and sponsored by Pfizer. This meeting is intended for healthcare professionals. © Pfizer Inc. August 2024. PP-UNP-GLB-2404.

Setting a new benchmark for ALK+ aNSCLC targeted therapy

view the full invitation

Pfizer

